Ireland - English Select A Country Media Room


Our discovery and development process always begins with the patient. We ask these important questions: How are patient needs not currently being met? How can we improve their treatment options? How can we work toward better outcomes? Starting with patient needs helps us focus our efforts and keeps our eye on our goal: to help patients improve their health and their lives.


Our discovery and development efforts are focused on a core set of therapeutic areas where we have proven expertise and where we believe we can have an even greater impact on the disease and how it is managed. These core areas of focus include neuroscience, virology, immunology, oncology and general medicine.

Read more about medicines we’re developing in these areas in Pipeline.


Unwavering in our commitment to bring the best science to patients worldwide.


As leading experts in autoimmune diseases and therapies, we focus on treatments that will improve the standard of care for this generation and the next. We continue to push innovation within our immunology pipeline—considering multiple scientific approaches and investigating novel solutions to help improve patient care across a variety of autoimmune diseases with unmet needs.

  • 150+ active clinical trials in immunology
  • 6 new molecular compounds in Phase I, II or III clinical trials in immunology
  • 9 immune-mediated inflammatory conditions being investigated
  • 50+ countries with active clinical trials in immunology


Committed to improving the lives of people affected by cancer. Cancer is smart and ever-evolving. The same is true of our approach to attacking cancer. We collaborate with an extraordinary group of scientists, physicians, industry peers and patients to continually improve our understanding of cancer. Together, we work to tackle the toughest challenges in oncology.

  • 16 new molecular compounds in Phase I, II or III clinical trials in oncology
  • 200+ active clinical trials in oncology
  • 20+ different cancers and tumor types being investigated


We are advancing research across several neurodegenerative disorders, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

On May 18, 2016, AbbVie opened a 43,000-square-foot Foundational Neuroscience Center (FNC) in Cambridge, Massachusetts. At the FNC, we will undergo research to gain a deeper understanding of the biological mechanisms underlying neurodegenerative diseases. Our goal is to identify novel therapeutic approaches for bringing relief to our patients living with these chronic, debilitating diseases.


We strive to break new ground in comprehensive care for patients living with the hepatitis C virus. The hepatitis C virus (HCV) was once a hard to treat, chronic disease, but the availability of new treatments such as direct-acting antivirals (DAAs), which can virologically combat the disease in specific genotypes, are impacting the way we care for chronic HCV patients. Together with the HCV community, we are working to help end HCV through awareness, screening, diagnosis and linkage to care programmes.

General Medicine

We continue to focus on research and development for other disease areas of significant need, always with an improved quality of life for patients in mind.


The AbbVie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The AbbVie Internet site that you have requested may be in a language that differs from your country of origin.

The AbbVie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this AbbVie site?



The “Yes” link below will take you out of AbbVie family of websites.

Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?